{
"id":"mk19_b_hm_q036",
"number":36,
"bookId":"hm",
"correctAnswer":"B",
"title":"Question 36",
"stimulus":[
{
"type":"p",
"hlId":"a8110d",
"children":[
"A 68-year-old woman is seen in consultation regarding recently diagnosed ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"JAK2"
]
},
" V617F mutation–positive essential thrombocythemia. She is asymptomatic, has no other medical problems, and takes no medications."
]
},
{
"type":"p",
"hlId":"aaab9d",
"children":[
"On physical examination, vital signs are normal. The spleen is palpable 2 cm below the left costal margin."
]
},
{
"type":"p",
"hlId":"602ea8",
"children":[
"Laboratory studies show a ",
{
"type":"reference-range-link",
"referenceRange":"Hemoglobin, blood",
"children":[
"hemoglobin"
]
},
" level of 13.5 g/dL (135 g/L), ",
{
"type":"reference-range-link",
"referenceRange":"Leukocyte count",
"children":[
"leukocyte count"
]
},
" of 6000/μL (6 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L), and ",
{
"type":"reference-range-link",
"referenceRange":"Platelet count",
"children":[
"platelet count"
]
},
" of 685,000/μL (685 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L)."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"1054f1",
"children":[
"Which of the following is the most appropriate treatment?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Aspirin"
}
},
{
"letter":"B",
"text":{
"__html":"Hydroxyurea plus aspirin"
}
},
{
"letter":"C",
"text":{
"__html":"Ruxolitinib"
}
},
{
"letter":"D",
"text":{
"__html":"Stem cell transplantation"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"4014bc",
"children":[
"In patients with essential thrombocythemia who have the ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"JAK2"
]
},
" V617F mutation, hydroxyurea plus aspirin should be the initial treatment choice."
]
},
{
"type":"keypoint",
"hlId":"49f65e",
"children":[
"Patients with essential thrombocythemia who are older than 60 years should be treated with aspirin and hydroxyurea regardless of mutation status."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"265aca",
"children":[
"Hydroxyurea plus aspirin is the most appropriate treatment for this patient (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"). Her diagnosis of essential thrombocythemia (ET) is based on the presence of the ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"JAK2"
]
},
" V617F mutation and elevated platelet count with normal leukocyte count and hemoglobin level. ET is a chronic myeloproliferative neoplasm, with the ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"JAK2"
]
},
" mutation being the most common, occurring in approximately 50% to 60% of patients; the ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"CAL-R"
]
},
" mutation is seen in 25% to 35% of patients, and 5% have the ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"MPL"
]
},
" mutation. Patients with ET and an underlying ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"JAK2"
]
},
" mutation are at higher risk for developing thrombotic complications than those with the ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"CAL-R"
]
},
" or ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"MPL"
]
},
" mutations, and aspirin is recommended in this population. Aspirin is also recommended for those older than 60 years regardless of mutation status. Cytoreductive therapy, which is aimed at decreasing the platelet count, is accepted care in those older than 60 years, as well as those with a history of thrombosis regardless of age. Cytoreductive medications include hydroxyurea, interferon, and anagrelide. Hydroxyurea is often used initially because of its tolerability and efficacy. Because the myelosuppressive effects are not specific to platelets, it is necessary to monitor for leukopenia and anemia."
]
},
{
"type":"p",
"hlId":"86b749",
"children":[
"Because this patient is older than 60 years, hydroxyurea should be included in the treatment plan. Aspirin alone would be insufficient (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
")."
]
},
{
"type":"p",
"hlId":"7e2ed2",
"children":[
"Ruxolitinib is an oral ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"JAK1/JAK2"
]
},
" inhibitor approved for use in polycythemia vera and myelofibrosis (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"). It has been shown to be effective at reducing spleen volume and symptom burden in these diseases, but it is not approved for use in ET."
]
},
{
"type":"p",
"hlId":"874c4e",
"children":[
"Stem cell transplantation is the only curative option in ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BCR-ABL"
]
},
"–negative myeloproliferative neoplasms (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). However, stem cell transplantation has an associated mortality risk and significant potential morbidity. Therefore, it is not considered in patients with ET or polycythemia vera because prognosis in these diseases is generally excellent with other therapies. Stem cell transplantation is typically reserved for those with higher risk myelofibrosis whose prognosis is otherwise estimated to be poor."
]
}
],
"relatedSection":"mk19_b_hm_s2_3_3",
"objective":{
"__html":"Treat essential thrombocythemia with the <i>JAK2</i> V617F mutation."
},
"references":[
[
"Tefferi A, Pardanani A. Essential thrombocythemia. N Engl J Med. 2019;381:2135-2144. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31774958",
"target":"_blank"
},
"children":[
"PMID: 31774958"
]
},
" doi:10.1056/NEJMcp1816082"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":29,
"B":65,
"C":6,
"D":0,
"E":0
},
"hlIds":[
"a8110d",
"aaab9d",
"602ea8",
"1054f1",
"4014bc",
"49f65e",
"265aca",
"86b749",
"7e2ed2",
"874c4e"
]
}